产品
编 号：F275171
分子式：C10H12FN5O4
分子量：285.23
分子式：C10H12FN5O4
分子量：285.23
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
397
In-stock
10mg
600
In-stock
25mg
1143
In-stock
50mg
1828
In-stock
100mg
2560
In-stock
结构图
CAS No: 21679-14-1
产品详情
生物活性：
Fludarabine (NSC 118218) is a DNA synthesis inhibitor and a fluorinated purine analogue with antineoplastic activity in lymphoproliferative malignancies. Fludarabine inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes.
体内研究：
Fludarabine (0.8?mg/kg; i.p.; two cycles for 5 days every 2 weeks) in combination with Cyclophosphamide (400?mg/kg; i.p.; 2 weeks) decreases incidence of GVHD.Animal Model:F-1 mice received 105 BCL-1 leukemia cells
Dosage:0.8?mg/kg
Administration:Intraperitoneal injection; two cycles for 5 days every 2 weeks
Result:Combination with Cyclophosphamide decreased incidence of graft-versus-host disease (GVHD).
体外研究：
Fludarabine (5 μM; 48?hours) induces a decrease in p27kip1 expression.
Fludarabine (NSC 118218) is a DNA synthesis inhibitor and a fluorinated purine analogue with antineoplastic activity in lymphoproliferative malignancies. Fludarabine inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes.
体内研究：
Fludarabine (0.8?mg/kg; i.p.; two cycles for 5 days every 2 weeks) in combination with Cyclophosphamide (400?mg/kg; i.p.; 2 weeks) decreases incidence of GVHD.Animal Model:F-1 mice received 105 BCL-1 leukemia cells
Dosage:0.8?mg/kg
Administration:Intraperitoneal injection; two cycles for 5 days every 2 weeks
Result:Combination with Cyclophosphamide decreased incidence of graft-versus-host disease (GVHD).
体外研究：
Fludarabine (5 μM; 48?hours) induces a decrease in p27kip1 expression.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备